Gold prices just lower; monthly gains on track
Investing.com - Bernstein SocGen Group lowered its price target on Revvity Inc (NYSE:RVTY) to $115.00 from $120.00 on Tuesday, while maintaining a Market Perform rating on the stock. According to InvestingPro data, the company maintains strong fundamentals with a perfect Piotroski Score of 9, indicating robust financial health.
The price target reduction follows Revvity’s second-quarter 2025 results released on Monday, which showed organic growth of 3% matching consensus estimates, while earnings per share of $1.18 exceeded analyst expectations of $1.14 by 3.5%.
Despite meeting quarterly expectations, Revvity reduced its full-year guidance, now projecting organic revenue growth of 2%-4%, earnings per share of $4.85-$4.95, and operating margin of 27.1%-27.3%.
The company’s stock fell approximately 8% after the announcement, primarily due to new pressure on Revvity’s immunodiagnostics business in China, which represents about 6% of the company’s revenue.
Bernstein noted that while Revvity’s year-to-date performance now aligns more closely with industry peers, the firm continues to see limited catalysts for additional value creation, citing muted sales in academic, government, and pharmaceutical instruments sectors, along with continued challenges in the Chinese immunodiagnostics market for several quarters ahead.
In other recent news, Revvity Inc. reported its second-quarter 2025 earnings, surpassing analyst expectations. The company achieved an adjusted earnings per share of $1.18, outperforming the forecasted $1.14. Additionally, Revvity’s revenue reached $720 million, exceeding the anticipated $710.39 million. Despite this positive earnings report, Jefferies recently lowered its price target for Revvity to $100 from $106, while maintaining a Hold rating. This adjustment was influenced by Revvity’s guidance related to China’s drug-related group policies, which are expected to impact the company’s financial outlook. These developments highlight the mixed reactions from analysts and investors regarding Revvity’s recent performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.